One in three people over the age 65 will develop Alzheimer’s. Currently, there is no cure for this devastating illness; however, there is good news on the horizon. A new drug therapy could halt deterioration in people with early symptoms of Alzheimer’s.

The drug, intravenous immunoglobulin (IVIg), prevents the decline of cognitive skills, memory, and the ability to live independently, among patients with mild to moderate symptoms of Alzheimer’s. A small number of patients who took the highest dosage of the drug for three years showed no decline in memory. This latest finding in the battle against Alzheimer’s was revealed at the Alzheimer’s Association International Conference in Vancouver, British Columbia. A larger study involving 400 patients will be concluded in a year.